- InVivo Therapeutics Announces $12 Million Registered Direct Offering
- InVivo Therapeutics Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial
- InVivo Therapeutics Reports Three-Month Update of First Acute Spinal Cord Injury Subject Implanted with Neuro-Spinal Scaffold
- InVivo Therapeutics Announces Reopening of Enrollment for Ongoing Pilot Trial
- InVivo Therapeutics Announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial
Developing Technology For The Treatment of Spinal Cord Injuries
InVivo Therapeutics Corporation is developing and intends to commercialize groundbreaking technologies for the treatment of spinal cord injuries (SCI). InVivo intends to leverage its platform technology to deliver several products to the market.